Rigel Pharmaceuticals, Inc. (RIGL)
Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer.
Rigel Provides Fourth Quarter and Full Year 2025 Financial Results and ...
Mar 3, 2026 · These forward-looking statements include, without limitation, anticipated financial performance for 2026; anticipated timing and results from the clinical development of R289; Rigel's …
Investor Relations :: Rigel Pharmaceuticals, Inc. (RIGL)
Feb 3, 2026 · Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel, small molecule drugs that significantly improve the lives of patients with immune …
Pipeline :: Rigel Pharmaceuticals, Inc. (RIGL)
Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and …
Rigel Provides Business Update and 2026 Outlook
Jan 12, 2026 · Rigel does not undertake any obligation to update forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future …
Products :: Rigel Pharmaceuticals, Inc. (RIGL)
Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and …
Rigel Reports Third Quarter 2025 Financial Results and Provides ...
Nov 4, 2025 · Rigel does not undertake any obligation to update forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future …
Rigel Reports First Quarter 2025 Financial Results and Provides ...
May 6, 2025 · The revenue ranges above exclude approximately $40.0 million in non-cash revenue that Rigel expects to recognize in the second quarter of 2025 related to the release of the remaining cost …
Rigel Presents Updated Data from the Ongoing Phase 1b Study …
Dec 7, 2025 · Rigel's open-label Phase 1b study of R289 is evaluating the safety, tolerability, pharmacokinetics and preliminary efficacy in patients with R/R lower-risk MDS (NCT05308264). …
Rigel Announces Publication of Final ARROW Clinical Trial Data on ...
Mar 31, 2026 · SOUTH SAN FRANCISCO, Calif., March 31, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on …